ATE432275T1 - Pyrrol- bzw. imidazolamide zur behandlung von obesitas - Google Patents
Pyrrol- bzw. imidazolamide zur behandlung von obesitasInfo
- Publication number
- ATE432275T1 ATE432275T1 AT05735382T AT05735382T ATE432275T1 AT E432275 T1 ATE432275 T1 AT E432275T1 AT 05735382 T AT05735382 T AT 05735382T AT 05735382 T AT05735382 T AT 05735382T AT E432275 T1 ATE432275 T1 AT E432275T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- imidazolamide
- obesitas
- pyrrole
- compounds
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04102005 | 2004-05-10 | ||
| PCT/EP2005/004416 WO2005108393A1 (en) | 2004-05-10 | 2005-04-25 | Pyrrole or imidazole amides for treating obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE432275T1 true ATE432275T1 (de) | 2009-06-15 |
Family
ID=34965432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05735382T ATE432275T1 (de) | 2004-05-10 | 2005-04-25 | Pyrrol- bzw. imidazolamide zur behandlung von obesitas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7563910B2 (de) |
| EP (1) | EP1749002B1 (de) |
| JP (1) | JP2007536298A (de) |
| KR (1) | KR100870346B1 (de) |
| CN (1) | CN1950361A (de) |
| AT (1) | ATE432275T1 (de) |
| AU (1) | AU2005240734A1 (de) |
| BR (1) | BRPI0510679A (de) |
| CA (1) | CA2564986A1 (de) |
| DE (1) | DE602005014632D1 (de) |
| ES (1) | ES2324720T3 (de) |
| MX (1) | MXPA06012813A (de) |
| RU (1) | RU2380367C2 (de) |
| WO (1) | WO2005108393A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8084451B2 (en) * | 2005-01-10 | 2011-12-27 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
| WO2007097276A1 (ja) | 2006-02-20 | 2007-08-30 | Astellas Pharma Inc. | ピロール誘導体またはその塩 |
| AU2007226673A1 (en) * | 2006-03-10 | 2007-09-20 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| CN102015637B (zh) * | 2008-02-06 | 2014-05-21 | 第一三共株式会社 | 苯基吡咯衍生物 |
| EP2800745B1 (de) | 2011-12-02 | 2020-02-12 | Phenex Pharmaceuticals AG | Pyrrolocarboxamid-verbindungen als modulatoren von mit orphan-nuklearrezeptor rar zusammenhängender orphan-rezeptor-gamma-aktivität (rory-nr1f3-aktivität) und zur behandlung chronischer entzündungs- und autoimmunerkrankungen |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| CA3268467A1 (en) * | 2022-09-27 | 2024-04-04 | University Of Florida Research Foundation, Incorporated | SMALL MOLECULES HIV-1 TAT PROTEIN DEGRADING AGENTS |
| WO2025172494A1 (en) | 2024-02-16 | 2025-08-21 | F. Hoffmann-La Roche Ag | Novel reversible fluorescent probes for cb1 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940418A (en) | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| IL141769A0 (en) | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| HK1046139B (zh) | 1999-03-29 | 2004-12-10 | 霍夫曼-拉罗奇有限公司 | 葡糖激酶活化剂 |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| JP2004502642A (ja) * | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| US6479479B2 (en) | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| PL208098B1 (pl) | 2000-03-23 | 2011-03-31 | Solvay Pharm Bv | Pochodne 4,5-dihydro-1H-pirazolu, kompozycja farmaceutyczna, sposób wytwarzania związków oraz ich zastosowanie |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| JP2002210238A (ja) * | 2001-01-24 | 2002-07-30 | Sony Computer Entertainment Inc | 記録媒体、プログラム、プログラム実行システム及びプログラム実行装置 |
| AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| PE20030547A1 (es) | 2001-09-24 | 2003-08-18 | Bayer Corp | Derivados de imidazol para el tratamiento de la obesidad |
| JP2005532982A (ja) | 2001-09-24 | 2005-11-04 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満の処置のためのピロール誘導体の製造及び使用 |
| AU2003209388A1 (en) * | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
-
2005
- 2005-04-25 ES ES05735382T patent/ES2324720T3/es not_active Expired - Lifetime
- 2005-04-25 AU AU2005240734A patent/AU2005240734A1/en not_active Abandoned
- 2005-04-25 RU RU2006143596/04A patent/RU2380367C2/ru not_active IP Right Cessation
- 2005-04-25 DE DE602005014632T patent/DE602005014632D1/de not_active Expired - Lifetime
- 2005-04-25 KR KR1020067023490A patent/KR100870346B1/ko not_active Expired - Fee Related
- 2005-04-25 WO PCT/EP2005/004416 patent/WO2005108393A1/en not_active Ceased
- 2005-04-25 AT AT05735382T patent/ATE432275T1/de active
- 2005-04-25 CN CNA2005800147749A patent/CN1950361A/zh active Pending
- 2005-04-25 BR BRPI0510679-6A patent/BRPI0510679A/pt not_active IP Right Cessation
- 2005-04-25 CA CA002564986A patent/CA2564986A1/en not_active Abandoned
- 2005-04-25 EP EP05735382A patent/EP1749002B1/de not_active Expired - Lifetime
- 2005-04-25 MX MXPA06012813A patent/MXPA06012813A/es active IP Right Grant
- 2005-04-25 JP JP2007511942A patent/JP2007536298A/ja active Pending
- 2005-05-09 US US11/125,382 patent/US7563910B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1749002B1 (de) | 2009-05-27 |
| RU2006143596A (ru) | 2008-06-20 |
| KR100870346B1 (ko) | 2008-11-25 |
| BRPI0510679A (pt) | 2007-12-26 |
| RU2380367C2 (ru) | 2010-01-27 |
| AU2005240734A1 (en) | 2005-11-17 |
| DE602005014632D1 (de) | 2009-07-09 |
| CN1950361A (zh) | 2007-04-18 |
| US7563910B2 (en) | 2009-07-21 |
| JP2007536298A (ja) | 2007-12-13 |
| CA2564986A1 (en) | 2005-11-17 |
| EP1749002A1 (de) | 2007-02-07 |
| MXPA06012813A (es) | 2007-01-26 |
| KR20070009686A (ko) | 2007-01-18 |
| US20050250769A1 (en) | 2005-11-10 |
| ES2324720T3 (es) | 2009-08-13 |
| WO2005108393A1 (en) | 2005-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE517882T1 (de) | Chinolinderivate | |
| EA201070422A1 (ru) | Производные оксадиазола | |
| MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| SE0203713D0 (sv) | Novel compounds | |
| EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| EA201000098A1 (ru) | Производные хиназолинамида | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
| ATE384058T1 (de) | Thiazolderivate | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| TW200407305A (en) | Novel compounds | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
| DE602006017980D1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
| ATE466854T1 (de) | 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren | |
| DE602007011434D1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1749002 Country of ref document: EP |